Impact of infectious diseases specialist evaluation on the rational use of antibiotics in patients with Streptococcus pneumoniae bacteremia;Impacto de la evaluación infectológica en el uso racional de antimicrobianos en pacientes con bacteriemia por Streptococcus pneumoniae

Revista Chilena de Infectologia

Volumn 24, Issue 4, 2007, Pages 264-269

  Mella Montecinos, Sergio ^a,b   Blamey D , Rodrigo ^a,b   Paiva M , Oriana ^b   Yáñez V , Jorge ^b   Riedel M , Gisela ^a   Aylwin R , Mabel ^a   Chabouty G , Hanriete ^b   Ortega R , Carlos ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b Hospital Regional de Concepcion Dr Guillermo Grant Benavente   (Chile)

Author keywords

Bacteremia; Penicillin; Pneumococcal pneumonia; Resistance

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; LOBAR PNEUMONIA; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PENICILLIN RESISTANCE; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE;

EID: 34548808537     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Edwards K M. Pneumococcal infections: therapeutics strategies and pitfalls. The pneumococcus. Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG editors. Washington: ASM Press American Society for Microbiology 2004; p 314-30.
2. Trampuz A, Widmer A F, Fluckiger U, Haenggi M, Frei R, Zimmerli W. Changes in the epidemiology of pneumococcal bacteremia in a Swiss university hospital during a 15 year period, 1986-2000. Mayo Clin Proc 2004; 79: 604-12.
3. Hook E W, Horton C A, Schaberg D R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249: 1055-7.
4. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60-759-76.
5. Fine M J, Smith M A, Carson C A, Mutha S S, Sankey S S, Weissfeld L A, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
6. Saldías F, O'Brien A, Gederlini A, Farías G, Díaz A. Neumonía adquirida en la comunidad en el anciano inmunocompetente que requiere hospitalización. Cuadro clínico, factores pronósticos y tratamiento. Arch Bronconeumol 2003; 39: 333-40.
7. Shariatzadeh M R, Huang J Q, Tyrrell G J, Johnson M M, Marrie T J. Bacteremic pneumococcal pneumonia. A prospective study in Edmonton and neighboring municipalities. Medicine 2005; 84: 147-61.
8. Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107: 34-43.
9. Gransden W R, Eykyn S J, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas's hospital Br Med J 1985; 290: 505-8.
10. Ambrose K, Stephens D S. Macrolide, quinolone, and other non β-lactam antibiotic resistance in Streptococcus pneumoniae. The pneumococcus. Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG editors. Washington: ASM Press American Society for Microbiology 2004; p 350-66.
11. Niederman M S, Mandell L A, Anzueto A, Bass J B, Broughton W A, Campbell G D, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
12. Mandell L A, Bartlett J G, Dowell S F, File Jr T M, Musher D M, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
13. Lagos R, Muñoz A, Valenzuela M T, Heitman I, Levine M M. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatric Infect Dis J 2002; 21: 1115-23.
14. Inostroza J, Trucco O, Prado V, Vinet A M, Retamal G, Ossa G, et al. Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in two chilean cities. Clin Diagn Lab Immunol 1998; 5: 176-80.
15. Soler T, Salamanca L, Arbo G, Molina E. Estudio de sensibilidad in vitro de cepas de Streptococcus pneumoniae de infecciones respiratorias bajas en el Instituto Nacional del Tórax (INT). Rev Méd Chile 2002; 130: 304-8.
16. Fernández M, Zagolín M, Ruiz M, Martínez M A, Díaz J C. Neumonía adquirida en la comunidad que se hospitaliza. Estudio etiológico. Rev Méd Chile 2003; 131: 498-504.
17. Díaz A, Alvarez M, Callejas C, Rosso R, Schnettler K, Saldías F. Clinical picture and pronostic factors for severe community-acquired pneumonia in adults admitted to the intensive care. Arch Bronconeumol 2005; 41: 20-6.
18. Noriega L M, González P, Canals C, Michaud P. Streptococcus pneumoniae septicemia. Análisis of 40 cases. Rev Méd Chile 1994; 122: 1385-92.
19. Rioseco M L, Riquelme R. Neumonía neumocócica bacterémica en 45 adultos inmunocompetentes hospitalizados. Cuadro clínico y factores pronósticos. Rev Méd Chile 2004; 132: 588-94.
20. Altuzarra R, Valenzuela M T, Trucco O, Inostroza J, Granata P, Fleiderman J, et al. Portación nasal de Streptococcus pneumoniae en adulto mayor y su respuesta frente a la vacunación antineumocócica. Rev Méd Chile 2007; 135: 160-6.
21. Saldías F, Flores L J, Torres C, García P, Díaz F. Susceptibilidad a antimicrobianos de Streptococcus pneumoniae en población infantil y adulta de Santiago. Período 1997-2003. Rev Méd Chile 2005; 133: 42-9.
22. Díaz A, Labarca J, Pérez C, Ruiz M, Wolff M. Tratamiento de la neumonía del adulto adquirida en la comunidad. Rev Chil Infect 2005; 22(Supl 1): 52-66.
23. Mella S, Blamey R, Riedel G, Aylwin M, Chabouty H. Utilidad de penicilina G en el tratamiento de la neumonía neumocócica. Rev Chil Infect 2005; 22: 377-8.
24. Waterer G W, Jennigs S G, Wunderink R G. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999; 116: 1278-81.
25. Campbell S G, Marrie T J, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia. A prospective observational study. Chest 2003; 123: 1142-50.
26. Rioseco M L, Riquelme R. Replica a la carta bacteriemia neumocócica y antibióticos. Rev Méd Chile 2004; 1260-1.
27. White A C Jr, Atmar R L, Wilson J, Cate T R, Stager C E, Greenberg S B. Effects of requiring prior authorization for selected antimicrobials expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25: 230-9.
28. Shlaes D M, Gerding D N, John Jr, JF, Craig W A, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-9.
29. Elliot J, Facklam R. Manual de laboratorio para la identificación y prueba de susceptibilidad a los antimicrobianos de importancia para la Salud Pública en el mundo en desarrollo. Haemophilus infuenzae, Neisseria meningitidis, Streptococcus pneumoniae, Neisseria gonorrhoeae, Salmonella serotipo Typhi, Shigella y Vibrio cholerae. Centros para el Control y la Prevención de Enfermedades: Centro Nacional para las Enfermedades Infecciosas (CDC) y Organización Mundial de la Salud, Enfermedades Transmisibles: Vigilancia y Respuesta. 2004.
30. Dowson C G. What is a pneumococcus? In: The pneumococcus. Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG editors. Washington: ASM Press American Society for Microbiology 2004; p 3-14.
31. Janoff E N, Rubins J. Immunodeficiency and invasive pneumococcal disease. In: The pneumococcus. Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG editors. Washington: ASM Press American Society for Microbiology 2004; p 252-80.
32. th Ed 2005; p 2392-411.
33. Pekka Nuorti J, Butler J C, Farley M M, Harrison L H, McGeer A, Kolczak M S, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000; 342: 681-9.
34. th edition. CLSI document M2-A9. Clinical and Laboratory Standards Institute, Wayne, Pa. 2006.
35. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute. Wayne, Pa. 2006.
36. Perlino C, Rimland D. Alcoholism, leukopenia and pneumococcal sepsis. Am Rev Res Dis 1985; 132: 757-60.
37. Solomkin J S, Fant W K, Rivera J O, Alexander J W. Randomized trial of imipenem-cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985; 78 (Suppl 6A): 85-91.
38. Podnos Y D, Jiménez J C, Wilson S E. Intra-abdominal sepsis in elderly persons. Clin Infect Dis 2002; 35: 62-8.
39. Valdivieso F, Trucco O, Prado V, Díaz M C, Ojeda A. Antimicrobial resistance of agents causing urinary tract infections in 11 chilean hospitals. PRONARES project. Rev Méd Chile 1999; 127: 1033-40.
40. Wolff M. Rol actual de los antibióticos tradicionales. Rev Chil Infect 1994; 11: 201-9.
41. Spellberg B, Powers J, Brass E, Miller L G, Edwards J E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86.
42. Dancer S J. The problem with cephalosporins. J Antimicrob Chemother 2001; 48: 463-78.
43. Medeiros A A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24 (Suppl 1): 19-45.
44. Hanson N D. AmpC β-lactamases: what do we need to know for the future? J Antimicrob Chemother 2003; 52: 2-4.
45. Patterson J E. Extended-spectrum beta-lactamases. Sem Res Crit Care Med 2003; 24: 79-87.
46. Chambers H F. Other β-lactam antibiotics. In Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Elsevier, 6th Ed 2005; p 311-8.
47. Adu A, Armour C L. Drug utilization review (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.
48. th Ed, USA 2005; p: 294-311.
49. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community acquired pneumonia. J Lab Clin Med 2004; 143: 269-83.
50. Musher D M, Bartlett J G, Doern G V. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med 2001; 161: 2538-44.
51. Hieber J P, Nelson J D. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297: 410-13.
52. Heffelfinger J D, Dowell S F, Jorgensen J H, Klugman K, Mabry L R, Musher D M, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-408.
53. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich P F, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
54. Feikin D R, Schuchat A, Kolczak M, Barrett N L, Harrison L H, Lefkowitz L. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-9.